A carregar...
Paclitaxel-resistant advanced recurrent breast cancer: a case of partial response due to addition of bevacizumab to paclitaxel therapy: a case report
BACKGROUND: Paclitaxel plus bevacizumab have shown a high response rate and prolonged progression-free survival in metastatic breast cancer patients. However, overall survival was not prolonged. Thus, no conclusion has been made on the effectiveness of bevacizumab. In our report, taxane plus bevaciz...
Na minha lista:
| Main Authors: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3707777/ https://ncbi.nlm.nih.gov/pubmed/23830415 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-0500-6-254 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|